NasdaqGS - Nasdaq Real Time Price USD

Zenas BioPharma, Inc. (ZBIO)

11.48

+0.47

+(4.27%)

At close: 4:00:00 PM EDT

11.65

+0.17

+(1.48%)

After hours: 4:52:33 PM EDT

Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates

- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Phase 2 MoonStone trial in Relapsing Multiple Sclerosis enrollment concluding; topline results expected early in the fourth quarter 2025 - - Enrollment of Phase 2 SunStone trial in Systemic Lupus Erythematosus expected to be completed by year-end 2025; topline results expected mid-2026 - - Strengthened leadership team with appointments of Lisa von Moltke, M.D., Head of Resea

GlobeNewswire 5 days ago

ZBIO
+4.27%
Zenas BioPharma Insiders US$407k Short Of Breakeven On Stock Purchase

Insiders who bought US$2.11m worth of Zenas BioPharma, Inc. ( NASDAQ:ZBIO ) stock in the last year have seen some of...

Simply Wall St. 27 days ago

ZBIO
+4.27%
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on April 15, 2025 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors (the “Committee”) granted non-qualified stock options to two newly hired officers of the Company, each as

GlobeNewswire last month

ZBIO
+4.27%
Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

Dr. Laken brings over 25 years of leadership experience in research, development operations, scientific assessment and strategyWALTHAM, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Haley Laken, Ph.D., as Chief Scientific Officer (CSO). Dr. Laken

GlobeNewswire last month

ZBIO
+4.27%
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress

On Thursday, Wedbush initiated coverage on Zenas BioPharma, Inc. (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company focused on developing therapies for autoimmune disease. Zenas BioPharma started trading on the NASDAQ in September 2024. The company closed an upsized initial public offering of 15.22 million shares at $17 per share, raising approximately $258.7 million in gross proceeds. The company’s lead program obexelimab concluded enrollment in the Phase 3 INDIGO trial for immuno

Benzinga last month

ZBIO
+4.27%
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointmen

GlobeNewswire 2 months ago

ZBIO
+4.27%
Is Zenas BioPharma (NASDAQ:ZBIO) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 2 months ago

ZBIO
+4.27%
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

- Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in third quarter 2025- -Topline results from pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (INDIGO) expected year-end 2025- - Enrollment of Phase 2 Trial in Systemic Lupus Erythematosus (SunStone) expected to be completed in 2025- - Out-licensed greater-China anti-IGF-1R Thyroid Eye Disea

GlobeNewswire 3 months ago

ZBIO
+4.27%
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced management’s fireside chat presentation at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 3:00 p.m. ET. A live webcast and archived replay of the Company’s presentation can

GlobeNewswire 3 months ago

ZBIO
+4.27%
Zenas BioPharma initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Zenas BioPharma (ZBIO) with a Buy rating and $30 price target The company’s lead autoimmune therapy, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and Fc gamma receptor IIb, FcgammaRIIb, broadly present on B cell lineage, the analyst tells investors in a research note. The firm believes obexelimab represents an autoimmune franchise molecule with the potential for B cell therapeutic differentiation. Published first on TheFly – t

TipRanks 4 months ago

ZBIO
+4.27%
Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Zenas BioPharma (ZBIO) to $35 from $40 and keeps an Overweight rating on the shares. The firm updated its model following Zenas’ recent announcement to not progress obexelimab to Phase 3 for warm autoimmune hemolytic anemia, but argues that current levels are “un-demanding” as Zenas heads towards data in 2025 that will address obexelimab’s competitive potential. Published first on TheFly – the ultimate source for real-time, market-moving breaking

TipRanks 5 months ago

ZBIO
+4.27%
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

-Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy- -Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related Disease (IgG4-RD)- -Advancing multiple obexelimab Phase 2 and Phase 3 clinical trials with results expected throughout 2025- WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Zenas

GlobeNewswire 6 months ago

ZBIO
+4.27%
Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

-INDIGO is the largest clinical trial conducted in patients living with IgG4-RD- -Topline INDIGO results expected by the end of 2025- WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the completion of its targeted enrollment for the Phase 3 INDIGO trial

GlobeNewswire 6 months ago

ZBIO
+4.27%
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences

WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the Company’s participation at the following healthcare investor conferences: Guggenheim’s Inaugural Healthcare Innovation Conference on November 12, 2024, in Boston, MAJefferies London Healthcare Conferen

GlobeNewswire 6 months ago

ZBIO
+4.27%
Opening Day: Another trio of biotech IPOs make Friday debut

The Partners Group-backed KinderCare sold 24 million shares for $24 each this Tuesday. At the IPO price, the childhood education company had a market value of $2.74B, based on the outstanding shares. Sky Quarry, Click Holdings, and SKK Holdings also opened for trading this week. Meanwhile, a new trio of biotech companies’ shares came to market on Friday as Upstream Bio, Ceribell and Camp4 Therapeutics each made their public debut. In mid-September, Bicara Therapeutics (BCAX), MBX Biosciences (MB

TipRanks 7 months ago

C

CBLL

ZBIO
+4.27%
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering

WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced that the underwriters of its previously announced upsized initial public offering of 13,235,294 shares of its common stock, which closed on September 16, 2024, exercised in full their option to purchase an additional 1,9

GlobeNewswire 7 months ago

ZBIO
+4.27%
Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Zenas. The gross proceeds from t

GlobeNewswire 8 months ago

ZBIO
+4.27%

Performance Overview

Return	ZBIO	S&P 500 (^GSPC)
YTD	+40.17%	+1.00%
1-Year	-37.44%	+11.91%
3-Year	-37.44%	+52.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Zenas BioPharma Insiders US$407k Short Of Breakeven On Stock Purchase

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress

Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

Is Zenas BioPharma (NASDAQ:ZBIO) In A Good Position To Invest In Growth?

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference

Zenas BioPharma initiated with a Buy at H.C. Wainwright

Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley

Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences

Opening Day: Another trio of biotech IPOs make Friday debut

Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

Performance Overview